Ventral hernias after cytoreductive surgery: how often they occur and how they are managed.
Incidence, Risk Factors and Surgical Management of Incisional Hernias Following Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Monocentric Cohort Study
This retrospective review tries to find how often adults who had cytoreductive surgery with or without HIPEC develop ventral hernias and which factors are linked to them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jules Bordet Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Anderlecht, Brussels Capital) |
| Trial ID | NCT07451483 on ClinicalTrials.gov |
What this trial studies
This is a retrospective observational review of adult patients treated with cytoreductive surgery (CRS) with or without HIPEC for pseudomyxoma peritonei, colorectal, or ovarian peritoneal carcinomatosis between 2010 and 2024 at a single center. Investigators will extract data from medical records to determine the incidence of postoperative ventral (incisional) hernias, identify associated patient- and surgery-related risk factors, and describe how hernias were managed surgically. No prospective interventions or follow-up are performed; cases with incomplete records or under one year of follow-up are excluded. The goal is to clarify rates and management patterns to inform future prevention and treatment strategies.
Who should consider this trial
Good fit: Adults aged 18 or older who underwent CRS ± HIPEC for pseudomyxoma peritonei, colorectal, or ovarian peritoneal carcinomatosis between January 1, 2010 and December 31, 2024 with complete records and at least one year of follow-up.
Not a fit: Patients with a prior ventral hernia at the planned incision site, those treated for primary cancers other than PMP/colorectal/ovarian peritoneal carcinomatosis, or those with incomplete records or under one year of follow-up are excluded and may not benefit from this analysis.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify patients at higher risk of ventral hernia after CRS ± HIPEC and inform follow-up, preventive measures, or timing/approach to repair to reduce morbidity.
How similar studies have performed: Previous single-center and retrospective series have reported widely varying hernia rates and suggested some risk factors, so this work builds on existing data but addresses persistent uncertainties rather than introducing a novel intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients (≥18 years) who underwent CRS +/- HIPEC for PMP, colorectal and ovarian PC between 01 January 2010 and 31 December 2024. Exclusion Criteria: * Patients with a prior history of ventral hernia at the planned incision site. * Patients undergoing CRS +/- HIPEC for primary cancer other than PMP, colorectal and ovarian PC. * Patients with incomplete medical records preventing data extraction. * Patients lost to follow-up within one year of surgery.
Where this trial is running
Anderlecht, Brussels Capital
- Jules Bordet Institute — Anderlecht, Brussels Capital, Belgium (Recruiting)
Study contacts
- Principal investigator: Gabriel Liberale, MD, Phd — Jules Bordet Institute
- Study coordinator: Gabriel Pr. Liberale, MD, PhD
- Email: gabriele.liberale@hubruxelles.be
- Phone: +32 477606766
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.